DelveInsight’s, “Head and Neck cancer Pipeline Insight, 2023,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Head and Neck cancer pipeline landscape. It covers the Head and Neck cancer pipeline drug profiles, including Head and Neck cancer clinical trial and nonclinical stage products. It also covers the Head and Neck cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Head and Neck Cancer Pipeline Report
Explore more about the latest breakthroughs of the Head and Neck Cancer Treatment Landscape @ Head and Neck Cancer Pipeline Outlook Report
Head and Neck Cancer Overview
Head and neck cancer is a collective term that includes several different types of cancers. Cancers of the head and neck are categorized by the area in which they begin. This includes the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. The most common type of head and neck cancer is squamous cell carcinoma of the head and neck (HNSCCA). Most HNSCCA begins in the layer of flat cells (the epithelium) which line the structures of the upper aerodigestive tract, including the mouth, throat, and voice box. HNSCCA accounts for about three to five percent of all cancers in the United States, where, in 2021, an estimated 54,000 people will be diagnosed with head and neck cancer and approximately 11,000 will die of the disease.
Recent Developmental Activities in the Head and Neck Cancer Treatment Landscape
Discover the recent advances in head and neck cancer treatment drugs @ Head and Neck Cancer Treatment Landscape
Head and Neck Cancer Emerging Drugs Profile
Monalizumab: Innate Pharma
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed on cancer cells of many solid tumors and hematological malignancies. Monalizumab may re-establish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies. Monalizumab is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting simultaneously on innate and adaptive immunity, monalizumab may re-establish a broad anti-tumor response. Currently, it is in Phase III stage of clinical trial evaluation to treat Squamous Cell Carcinoma of the Head and Neck.
Niraparib: GlaxoSmithKline
Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death. Increased niraparib-induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2. Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient-derived xenograft tumor models with homologous recombination deficiency that had either mutated or wild type BRCA1/2.
Xevinapant: Debiopharm
Xevinapant (Debio 1143) is a potential first-in-class potent oral antagonist of IAPs (Inhibitor of Apoptosis Proteins). In preclinical studies, xevinapant restores sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms. As the most clinically advanced IAP antagonist, xevinapant has established proof of efficacy in combination with chemoradiotherapy (CRT) in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), with a clinically significant and sustained clinical benefit compared with CRT alone.
Enoblituzumab: MacroGenics
Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 and has been enhanced using MacroGenics’ Fc Optimization platform. B7-H3 is a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer. MacroGenics is collaborating on the development and commercialization of enoblituzumab with I-Mab Biopharma in Greater China. MacroGenics retains full development and commercialization rights in all other territories. Currently, it is in Phase II stage of clinical trial evaluation to treat Head and Neck cancer.
Head and Neck Cancer Therapeutics Assessment
There are approx. 150+ key companies which are developing the therapies for Head and Neck cancer. The companies which have their Head and Neck cancer drug candidates in the most advanced stage, i.e. phase III include, Innate Pharma.
Learn more about the emerging head and neck cancer pipeline therapies @ Head and Neck Cancer Ongoing Clinical Trials Analysis
Scope of the Head and Neck Cancer Pipeline Report
Table of Content
For further information on the head and neck cancer pipeline therapeutics, reach out @ Head and Neck Cancer Market Drivers and Barriers
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/